Eli Lilly's retatrutide helps diabetes patients lose up to 21% body weight in late-stage trial
Eli Lilly reported that its experimental triple-agonist drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, with more than half of patients dropping below the obesity threshold.
